Alfuzosin for benign prostatic hyperplasia

This is the protocol for a review and there is no abstract. The objectives are as follows: This systematic review aims to assess the efficacy and safety of alfuzosin in the treatment of benign prostatic hyperplasia (BPH) versus placebo or active control. The main outcome measures include improvement in urologic symptom scale scores or global report of urinary symptoms or other urologic symptoms (improved versus stable or worsened). Secondary outcome measures included changes in urinary symptoms (nocturia, frequency, urgency, dribbling, peak and mean urine flow, residual urine volume, prostate size and side effects associated with the use of alfuzosin. Additionally, we wish to assess outcomes according to: history of hypertension; age > 65 years; and prostate size > 40 cc.